Sarah Klein, PhD profile page

Sarah Klein is an Associate Director at Cell Signaling Technology with over 9 years of experience in the life sciences industry driving scientific strategy and innovation, and developing multiplex technologies like the SignalStar mIHC which you’ll hear more about today. Prior to joining CST, Sarah dedicated 9 years of research to the preclinical characterization of cancer therapeutics. Sarah performed her postdoc at Dana-Farber Cancer Institute using syngeneic mouse models of cancer to evaluate the cellular and molecular response to immune checkpoint blockade, and her Ph.D. thesis research at MD Anderson Cancer Center investigating the therapeutic mechanisms of adenoviral-based vaccines for the treatment of brain tumors. Sarah’s expertise lies in utilizing multiplex technologies, particularly multiplex imaging, to evaluate response to cancer therapeutics in order to identify novel targets for combination therapies and potential biomarkers.